PROVE-IT: Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22

principal researchers

Eugene Braunwald (Brigham and Women's Hospital, Harvard Medical School)   

Christopher P Cannon (Brigham and Women's Hospital, Harvard Medical School)   

data custodian

TIMI Study Group, Brigham and Women's Hospital

funding

Bristol-Myers Squibb; Sankyo

key publications

• Design paper: Am J Cardiol 2002; 89: 860-861
• Main results: N Engl J Med 2004; 350: 1495-504
• Cardiovascular protection: Atheroscler Suppl. 2003; 4(5): 3-9 (248)
• Critical pathways for ACS:  Crit Pathw Cardiol. 2003; 2(3): 188-96 (249)
• Pleiotropic effects:  Am J Cardiol 2005; 96(5A): 54F-60F (250)
• Fracture incidence: Bone 2005; 37(2): 190-1 (251)
• LDL cholesterol and C-reactive: J Am Coll Cardiol 2005; 45(10): 1644-8 (252)
• Early and late benefits: J Am Coll Cardiol 2005; 46(8): 1405-10 (253)
• Can low-density lipoprotein be too low?: J Am Coll Cardiol 2005; 46(8): 1411-6 (254)
• C-reactive protein levels: J Am Coll Cardiol 2005; 46(8): 1417-24 (255)
• Management of ACS: J Am Coll Cardiol 2005; 46(8): 1425-33 (256)
• C-reactive protein: N Engl J Med. 2005; 352(1): 20-8 (257)
• Chlamydia pneumonia: N Engl J Med. 2005; 352(16): 1646-54 (258)
• Comparison with A to Z: Circulation 2006; 113(11): 1406-14 (259)
• Lipoprotein-associated phospholipase A2: Circulation 2006; 113(14): 1745-52 (260)
• Diabetes: Eur Heart J 2006; 27(19): 2323-9
• ACS and diabetes: Eur Heart J 2006; 27(19): 2323-9 (262)
• Risk of hospitalization for heart failure: J Am Coll Cardiol 2006; 47(11): 2326-31 (263)
• Cerebrovascular: J Thromb Thrombolys 2006; 22(1): 71-76 (264)
• Mortality: Am J Cardiol 2007; 100(7): 1047-51 (265)
• Long-term prognostic value of neopterin: Circulation 2007; 115(24): 3071-8 (266)
• Proton pump inhibitor use: Crit Pathw Cardiol 2007; 6(4): 169-72 (267)
• Myeloid-related protein 8/14: Am Heart J 2008; 155(1): 49-55 (268)
• Atrial fibrillation: Am Heart J 2008; 155(2): 298-302 (269)
• Clopidogrel treated patients: Am Heart J 2008; 155(5): 954-8 (270)
• Polymorphism in KIF6: J Am Coll Cardiol 2008; 51(4): 449-55 (271)
• Triglyceride levels: J Am Coll Cardiol 2008; 51(7): 724-30 (272)
• Baseline low-density lipoprotein cholesterol: J Am Coll Cardiol 2008; 52(11): 914-20 (273)
• Seasonal variation: Am J Cardiol 2009; 103(8): 1056-60 (274)
• Genetic variants: Arterioscl Throm Vas 2009; 29(9): 1310-5 (275)
• apoB/AI: Arterioscl Throm Vas 2009; 29(3): 424-30 (276)
• C-reactive protein and B-type natriuretic peptide: Clin Chem 2009; 55(2): 265-73 (277)
• Clinical outcomes:  J Am Coll Cardiol 2009; 54(24): 2290-5 (278)
• Cardiovascular events: J Am Coll Cardiol 2009; 54(25): 2358-62 (279)
• Traditional and novel risk factors: Am J Cardiol 2010; 105(5): 619-23 (280)
• Cholesteryl ester transfer protein mass: Am J Cardiol 2010; 106(4): 451-6 (281)
• Growth differentiation factor-15: Arterioscl Throm Vas 2011; 31(1): 203-10 (282)
• Office-based global cardiometabolic risk assessment: Crit Pathw Cardiol 2010; 9(3): 156-9 (283)
• Optimal blood pressure: Circulation 2010; 122(21): 2142-51 (284)
• Long-term C-reactive protein levels: J Thromb Thrombolys 2010; 30(1): 10-3 (285)
• Adiponectin: Am Heart J 2011; 161(6): 1147-55 e1. (286)
• Gender: Circ Cardiovasc Qual Outcomes 2011; 4(3): 328-36
• Neopterin and heart failure: Eur Heart J 2011; 32(11): 1390-7 (288)
• Genetic variants in the KIF6 region: Hum Genet 2011; 129(1): 17-23 (289)
• Risk of incident diabetes: JAMA 2011; 305(24): 2556-64 (290)
• Galectin-3 and heart: Clin Chem 2012; 58(1): 267-73 (291)
• C-reactive protein controversy: Eur Heart J 2012; 33(4): 430-2 (292)
• Placental growth factor: J Thromb Thrombolys 2012; 34(2): 222-8 (293)
• Urinary albumin concentration: J Thromb Thrombolys 2013; 36(3): 233-9 (294)
• Lipoprotein (a): J Am Coll Cardiol 2014; 63(6): 520-7 (295)
• Incidence of Kidney: J Am Heart Assoc 2014; 3(3): e000784 (296)